Tiziana life sciences announces study results from intranasal anti-cd3 foralumab in multiple sclerosis patients with pira highlighted in neurology today®

- intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (pira) - - data presented in a platform session at the annual meeting of the american academy of neurology in denver, colorado -
TLSA Ratings Summary
TLSA Quant Ranking